Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $8.20 Average Price Target from Brokerages

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been given an average rating of “Reduce” by the twelve analysts that are covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $8.20.

A number of brokerages have weighed in on FULC. Piper Sandler downgraded shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.00 target price for the company. in a research note on Tuesday, June 2nd. Citigroup cut Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a research report on Tuesday, June 2nd. Cantor Fitzgerald downgraded Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Wall Street Zen raised Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 2nd. Finally, Leerink Partners cut Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 price objective for the company. in a research note on Tuesday, June 2nd.

Insider Buying and Selling at Fulcrum Therapeutics

In other news, Director Alan Ezekowitz sold 18,000 shares of Fulcrum Therapeutics stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $3.65, for a total value of $65,700.00. Following the completion of the transaction, the director owned 10,927 shares of the company’s stock, valued at $39,883.55. The trade was a 62.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 7.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Deutsche Bank AG boosted its stake in shares of Fulcrum Therapeutics by 0.6% in the fourth quarter. Deutsche Bank AG now owns 287,096 shares of the company’s stock worth $3,247,000 after acquiring an additional 1,767 shares during the period. Intech Investment Management LLC grew its position in shares of Fulcrum Therapeutics by 14.5% during the fourth quarter. Intech Investment Management LLC now owns 19,747 shares of the company’s stock worth $223,000 after purchasing an additional 2,503 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Fulcrum Therapeutics during the 4th quarter valued at approximately $30,000. The Manufacturers Life Insurance Company lifted its holdings in Fulcrum Therapeutics by 25.0% in the 1st quarter. The Manufacturers Life Insurance Company now owns 16,102 shares of the company’s stock worth $124,000 after purchasing an additional 3,219 shares in the last quarter. Finally, Meeder Asset Management Inc. purchased a new position in Fulcrum Therapeutics in the 4th quarter worth approximately $39,000. 89.83% of the stock is owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Trading Down 1.6%

FULC opened at $3.69 on Friday. The stock has a fifty day simple moving average of $3.65 and a two-hundred day simple moving average of $6.58. The company has a market cap of $281.55 million, a price-to-earnings ratio of -3.05 and a beta of 3.05. Fulcrum Therapeutics has a 12-month low of $2.83 and a 12-month high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). On average, analysts predict that Fulcrum Therapeutics will post -0.69 EPS for the current year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small?molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.